Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Ovarian CancerRelapsed or RefractoryChiauranibPaclitaxel
Interventions
DRUG

chiauranib

50mg orally once daily

DRUG

Placebo

50mg orally once daily

DRUG

Paclitaxel

at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY